Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The entry "ribosomal protein L36a-like pseudogene" (noted in Ensembl as ENSG00000270378) refers to a processed pseudogene related to the genuine ribosomal protein L36a (RPL36A) and its closely related functional paralog RPL36A-like (RPL36AL)[1][3][5][6]. Pseudogenes are segments of DNA that resemble genes but are generally considered nonfunctional due to mutations or truncations that prevent them from being transcribed or translated into functional proteins. There are many processed pseudogenes for ribosomal proteins scattered throughout the human genome[4][5]. Pseudogenes do not encode active proteins and are not considered therapeutic targets, receptors, enzymes, or regulatory proteins. They rarely have a direct biological function or disease association and have no established role as drug targets, disease biomarkers, or pharmacological mechanisms. Key Details: - "Ribosomal protein L36a-like pseudogene" by definition is not a protein-coding gene and does not produce a functional protein[1][4][5]. - The gene product is not a receptor, enzyme, transporter, or other classically defined molecular target. - While some pseudogenes can have regulatory effects (e.g., acting as miRNA sponges), no such function is clearly reported for this pseudogene in available sources. - At least dozens of "ribosomal protein L36a pseudogenes" exist in the human genome, each distinguished by a numeral (e.g., RPL36AP1, RPL36AP10)[3]. Summary: This entry refers to a genomic pseudogene, not an active protein or drug target[1][3][5]. There is nothing to suggest therapeutic targeting or disease relevance. The name is correct for the pseudogene class, but this is not a therapeutic target and should be distinguished from its protein-coding relatives RPL36A or RPL36AL[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L36a-like pseudogene.